Scientific publications

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy

Oct 1, 2019 | Magazine: HemaSphere

Evangelos Terpos, Ioannis V Kostopoulos, Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Pantelis Rousakis, Alexandra T Argyriou, Nikolaos Kanellias, Despina Fotiou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Dimitrios C Ziogas, Aristea-Maria Papanota, Marilyn Spyropoulou-Vlachou, Ioannis P Trougakos, Ourania E Tsitsilonis, Bruno Paiva, Meletios A Dimopoulos


Abstract

Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10-5; 17% at 10-6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts' and tumor-associated monocytes/macrophages' predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10-6.

CITATION  Hemasphere. 2019 Oct 1;3(6):e300. doi: 10.1097/HS9.0000000000000300. eCollection 2019 Dec.

Our authors

Director | Principal Investigator Cytometry Platform